science pharmaceutical expo biotech jobs

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Crowe, S. M.
Right arrow Articles by Sonza, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crowe, S. M.
Right arrow Articles by Sonza, S.
(Journal of Leukocyte Biology. 2000;68:345-350.)
© 2000 by Society for Leukocyte Biology

HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication

Suzanne M. Crowe and Secondo Sonza

AIDS Pathogenesis Research Unit, Macfarlane Burnet Centre for Medical Research, Melbourne, Victoria, Australia

Correspondence: Prof. Suzanne M. Crowe, Macfarlane Burnet Centre for Medical Research, Yarra Bend Road, Fairfield, Victoria 3078, Australia. E-mail: tolli{at}burnet.edu.au

During highly active antiretroviral therapy (HAART), HIV-1 can still persist in circulating, resting CD4+ T lymphocytes, lymph node mononuclear cells, and seminal cells of patients despite sustained suppression of plasma viremia to undetectable levels. Sanctuary sites where antiretroviral drug penetration is not optimal may allow local HIV-1 infection of cells within and passing through these tissues. Factors such as imperfect drug adherence due to complicated drug regimens may also result in tissue compartments with suboptimal drug concentrations allowing viral replication. We have examined blood monocytes from HIV-1-infected subjects being effectively treated with HAART to determine virus carriage in these cells. Monocytes were purified from peripheral blood of patients with plasma HIV-1 RNA below 50 copies/mL and who had maintained levels of plasma RNA below detection for 3 months or more. Replication-competent virus could be recovered from the majority of monocyte populations by co-culture with CD8-depleted, PHA-activated, peripheral blood mononuclear cells. Sequencing of the reverse transcriptase and protease genes of the recovered viruses did not reveal resistance to both reverse transcriptase and protease inhibitors. Continued new infection of this transitory, circulating population of cells even during prolonged, effective HAART most likely reflects ongoing, low-level HIV-1 replication within cellular reservoirs and sanctuary sites in the body.

Key Words: reservoirs • macrophages • lymphocytes • persistence




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
I. Komuro, T. Sunazuka, K. S. Akagawa, Y. Yokota, A. Iwamoto, and S. Omura
Erythromycin derivatives inhibit HIV-1 replication in macrophages through modulation of MAPK activity to induce small isoforms of C/EBP{beta}
PNAS, August 26, 2008; 105(34): 12509 - 12514.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
L. Rossi, P. Franchetti, F. Pierige, L. Cappellacci, S. Serafini, E. Balestra, C.-F. Perno, M. Grifantini, R. Calio, and M. Magnani
Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir
J. Antimicrob. Chemother., April 1, 2007; 59(4): 666 - 675.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
E. Cassol, M. Alfano, P. Biswas, and G. Poli
Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence
J. Leukoc. Biol., November 1, 2006; 80(5): 1018 - 1030.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
M. Pinti, P. Biswas, L. Troiano, M. Nasi, R. Ferraresi, C. Mussini, J. Vecchiet, R. Esposito, R. Paganelli, and A. Cossarizza
Different Sensitivity to Apoptosis in Cells of Monocytic or Lymphocytic Origin Chronically Infected with Human Immunodeficiency Virus Type-1
Experimental Biology and Medicine, December 1, 2003; 228(11): 1346 - 1354.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S. Crowe, T. Zhu, and W. A. Muller
The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection
J. Leukoc. Biol., November 1, 2003; 74(5): 635 - 641.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. G. Brooks, P. A. Arlen, L. Gao, C. M. R. Kitchen, and J. A. Zack
Identification of T cell-signaling pathways that stimulate latent HIV in primary cells
PNAS, October 28, 2003; 100(22): 12955 - 12960.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
A. Fraternale, A. Casabianca, L. Rossi, L. Chiarantini, G. F. Schiavano, A. T. Palamara, E. Garaci, and M. Magnani
Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections
J. Antimicrob. Chemother., October 1, 2003; 52(4): 551 - 554.
[Full Text] [PDF]


Home page
JEMHome page
I. Komuro, Y. Yokota, S. Yasuda, A. Iwamoto, and K. S. Kagawa
CSF-induced and HIV-1-mediated Distinct Regulation of Hck and C/EBP{beta} Represent a Heterogeneous Susceptibility of Monocyte-derived Macrophages to M-tropic HIV-1 Infection
J. Exp. Med., August 4, 2003; 198(3): 443 - 453.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
S. Sonza, H. P. Mutimer, K. O'Brien, P. Ellery, J. L. Howard, J. H. Axelrod, N. J. Deacon, S. M. Crowe, and D. F. J. Purcell
Selectively Reduced tat mRNA Heralds the Decline in Productive Human Immunodeficiency Virus Type 1 Infection in Monocyte-Derived Macrophages
J. Virol., November 13, 2002; 76(24): 12611 - 12621.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
J. Rice, R. Connor, S. Worgall, J. P. Moore, P. L. Leopold, R. J. Kaner, and R. G. Crystal
Inhibition of HIV-1 Replication in Alveolar Macrophages by Adenovirus Gene Transfer Vectors
Am. J. Respir. Cell Mol. Biol., August 1, 2002; 27(2): 214 - 219.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
D. A. Davis, E. Read-Connole, K. Pearson, H. M. Fales, F. M. Newcomb, J. Moskovitz, and R. Yarchoan
Oxidative Modifications of Kynostatin-272, a Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor: Potential Mechanism for Altered Activity in Monocytes/Macrophages
Antimicrob. Agents Chemother., February 1, 2002; 46(2): 402 - 408.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
P. R. Gorry, G. Bristol, J. A. Zack, K. Ritola, R. Swanstrom, C. J. Birch, J. E. Bell, N. Bannert, K. Crawford, H. Wang, et al.
Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity
J. Virol., November 1, 2001; 75(21): 10073 - 10089.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Chougnet, C. Freitag, M. Schito, E. K. Thomas, A. Sher, and G. M. Shearer
In Vivo CD40-CD154 (CD40 Ligand) Interaction Induces Integrated HIV Expression by APC in an HIV-1-Transgenic Mouse Model
J. Immunol., March 1, 2001; 166(5): 3210 - 3217.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
L. J. Montaner, C.-F. Perno, and S. Crowe
Macrophage infection by HIV-1: focus on viral reservoirs and pathogenesis
J. Leukoc. Biol., September 1, 2000; 68(3): 301 - 302.
[Full Text] [PDF]